Exploring High Growth Tech Stocks in December 2024

In This Article:

Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable market conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.83%

24.32%

★★★★★★

Ardelyx

25.47%

69.63%

★★★★★★

Sarepta Therapeutics

24.00%

42.51%

★★★★★★

Alnylam Pharmaceuticals

22.35%

70.33%

★★★★★★

Clene

78.50%

60.16%

★★★★★★

TG Therapeutics

34.66%

56.98%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 245 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Exact Sciences

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Exact Sciences Corporation is a company that offers cancer screening and diagnostic test products both in the United States and internationally, with a market cap of approximately $11.21 billion.

Operations: Exact Sciences generates revenue primarily from its biotechnology segment, contributing approximately $2.69 billion. The company's focus is on cancer screening and diagnostic tests, serving both domestic and international markets.

Exact Sciences, a player in the high-stakes field of cancer diagnostics, recently showcased its resilience and innovation at multiple healthcare conferences. Despite a challenging fiscal quarter with sales rising to $708.66 million from $628.34 million year-over-year but facing a net loss increase to $38.24 million from a previous net income of $0.794 million, the company continues to invest heavily in research and development (R&D). This dedication is evident as R&D expenses surged by 9.2%, underscoring its commitment to pioneering advanced diagnostic solutions like the FDA-approved Cologuard Plus test, which outperformed traditional tests in detecting colorectal cancer with 95% sensitivity. Looking ahead, Exact Sciences anticipates leveraging its robust product pipeline and commercial infrastructure to enhance cancer screening rates across diverse populations, aiming for significant growth in earnings projected at 72.4% annually.